重大事项： 协鑫新能源(00451)拟发行1.865亿股认购股份 牵手 Pharos加速Web3与新能源产业的融合 翰森制药(03692)：阿美乐® (甲磺酸阿美替尼片)第五项适应症获国家药品监督管理局签发药品注册证书 绿叶制药(02186)：1类创新药若欣林®用于治疗广泛性焦虑障碍的新适应症中国上市申请获得受理 先健科技(01302)：G-iliacTM Pro髂动脉覆膜支架系统获得中国国家药品监督管理局的正式注册批准 美瑞健康国际(02327)拟1.25亿元收购江苏懿德全部股权 世纪娱乐国际(00959)合资公司与WPT订立谅解备忘录 拟共同开发、营运及实现移动应用程式的商业化 经营业绩： 迅销(06288)发布第一季度业绩，股东应占溢利1474.45亿日圆 同比增加11.7% 合景泰富集团(01813)12月预售额为4.20亿元 同比减少56.7% 宝龙地产(01238)2025年合约销售总额约72.72亿元 同比减少43.13% 中广核电力(01816)2025年总上网电量约为2326.48亿千瓦时 同比增长2.36% 灵宝黄金(03330)发盈喜 预计2025年度净利润约15.03亿至15.73亿元 ...

Core Insights - Green Leaf Pharmaceutical has received FDA approval to conduct clinical trials for its new generation 5-HT2AR inverse agonist and 5-HT2CR antagonist, LY03017, aimed at treating Alzheimer's disease psychotic disorder (ADP), Parkinson's disease psychotic disorder (PDP), and negative symptoms of schizophrenia (NSS) [1][2] - LY03017 is designed to target both 5-HT2AR and 5-HT2CR receptors, showing significant preclinical efficacy and safety advantages over existing and investigational drugs for the same indications [2] Group 1: Product Development - LY03017 is based on the company's new molecular entity platform and is being developed simultaneously in China and the U.S., currently in Phase I clinical trials in both regions [1] - The FDA has waived the single ascending dose (SAD) trial phase for LY03017, allowing the company to proceed directly to multiple ascending dose (MAD) trials and subsequent clinical studies [1] Group 2: Market Opportunity - There is currently only one FDA-approved drug for treating PDP, which has not yet been approved in China; no drugs are approved for ADP treatment, and only a few have limited efficacy for NSS, indicating a significant unmet medical need in these areas [1] - The central nervous system treatment sector is a core strategic focus for the company, with a diverse product portfolio addressing various mental health conditions, including depression, schizophrenia, and bipolar disorder [3] Group 3: Pipeline and Innovation - The company is actively developing next-generation innovative drugs, with several first-in-class candidates in clinical stages, including LY03015, LY03020, and LY03021, targeting multiple receptors [3]

Major Events - Double End Co., Ltd. plans to globally offer 58.557 million H-shares from August 18 to August 21, with San Shui Venture Capital as a cornerstone investor [1] - Sunac China intends to issue mandatory convertible bonds and adopt a team stability plan [1] - Ascentage Pharma-B received FDA and EMA approval for the global registration of its Phase III clinical trial for the treatment of high-risk MDS patients [1] - 361 Degrees' subsidiary entered into a strategic cooperation agreement with Stand [1] - Eagle Precision indicates that additional tariffs may impact its business and operations [1] - Green Leaf Pharmaceutical's clinical trial for the treatment of generalized anxiety disorder has completed patient enrollment in China [1] - Tian Tu Investment and HashKey Capital signed a strategic cooperation memorandum to establish a virtual asset investment fund [1] - China Rare Earth Holdings expects annual gold production from MtBundy and Cygnet gold projects to exceed 200,000 ounces [1] Operating Performance - Xinhua Insurance reported a cumulative original insurance premium income of 137.806 billion yuan in the first seven months, a year-on-year increase of 23% [1] - China Biologic Products announced mid-term revenue of 17.57 billion yuan, up 10.7% year-on-year [1] - Meitu Inc. reported a mid-term profit attributable to shareholders of 397 million yuan, a year-on-year increase of 30.84%, with strong growth in MAU and paid subscribers [1] - Xtep International reported a mid-term profit attributable to shareholders of 914 million yuan, a year-on-year increase of 21.47% [1] - Leap Motor achieved a net profit of 33.03 million yuan in the first half of the year, marking its first positive half-year net profit [1] - Hansoh Pharmaceutical reported a mid-term profit attributable to shareholders of 3.135 billion yuan, a year-on-year increase of 15.02% [1] - Kangzheng Pharmaceutical announced a mid-term profit attributable to shareholders of approximately 941 million yuan, a year-on-year growth of 3.38% [1] - Kelun-Bio reported mid-term revenue of 950 million yuan with R&D expenses of 612 million yuan [1] - Sinopec Oilfield Services reported a net profit of approximately 492 million yuan in the first half, a year-on-year increase of 9% [1] - Wanwu Cloud reported a mid-term profit attributable to shareholders of 792 million yuan, a year-on-year increase of 3.88% [1] - Yunfeng Financial expects a significant year-on-year increase of approximately 139% in net profit attributable to equity shareholders, estimated at around 480 million HKD for the first half [1] - United Pharmaceutical anticipates a mid-term net profit of approximately 1.85 billion yuan, a year-on-year increase [1] - Sipai Health reported a mid-term overall gross margin increase of 4.7 percentage points to 14.4% [1] - Orange Sky Golden Harvest expects a net profit attributable to shareholders of no less than 125 million HKD for the first half, marking a turnaround from loss to profit [1] - Baifu Global reported a mid-term profit attributable to shareholders of 391 million HKD, proposing an interim dividend of 0.25 HKD per share [1] - WuXi AppTec reported a mid-term profit attributable to shareholders of 746 million yuan, a year-on-year increase of 52.74% [1] - Joy City Property reported a total contract sales amount of approximately 2.749 billion yuan in the first half, a year-on-year decrease of 81.4% [1]

Core Viewpoint - The company, Green Leaf Pharmaceutical (02186.HK), is set to hold a board meeting on August 28, 2025, to approve its mid-term performance for the six months ending June 30, 2025, and to consider the distribution of an interim dividend, if applicable [1] Related Events - Green Leaf Pharmaceutical plans to hold a board meeting on August 28 to approve mid-term performance [1] - The company has completed patient enrollment for the Phase III clinical trial of Ruxolitinib for the treatment of generalized anxiety disorder in China [1]